Zivo Bioscience

Zivo Bioscience EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Zivo Bioscience (ZIVO) as of Oct 19, 2026 is -9.85 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -13.36 M USD — a change of -26.25% (higher).

EBITDA

-9.85 MUSD

YoY

-26.25%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Zivo Bioscience is 2025 -9.85 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Zivo Bioscience was 2024 -13.36 M USD. It decreases by -26.25% higher compared to the previous year.

The Zivo Bioscience EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-6.13 M USD
Jan 1, 2019
-8.35 M USD
Jan 1, 2020
-8.56 M USD
Jan 1, 2021
-9.05 M USD
Jan 1, 2022
-8.73 M USD
Jan 1, 2023
-7.27 M USD
Jan 1, 2024
-13.36 M USD
Jan 1, 2025
-9.85 M USD
The Zivo Bioscience EBITDA history
YEAREBITDAYoY
-9.85 MUSD-26.25%
-13.36 MUSD+83.75%
-7.27 MUSD-16.72%
-8.73 MUSD-3.54%
-9.05 MUSD+5.81%
-8.56 MUSD+2.43%
-8.35 MUSD+36.24%
-6.13 MUSD-3.15%
-6.33 MUSD+80.07%
-3.52 MUSD+15.02%
-3.06 MUSD-40.69%
-5.15 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Zivo Bioscience Stock analysis

What does Zivo Bioscience do? Zivo Bioscience Inc., headquartered in Keego Harbor, Michigan, develops and commercializes natural nutritional compounds and bioactive molecules derived from proprietary algal strains. The company focuses on research and development of bioactive ingredients for human and animal dietary supplements, medical foods, and pharmaceutical applications, particularly targeting autoimmune and inflammatory response modulation. With 8 employees, it operates in the Consumer Staples sector, specializing in natural health products and diagnostic testing solutions. Zivo Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Zivo Bioscience stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Zivo Bioscience is -9.85 M USD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Zivo Bioscience changed from -13.36 M USD to -9.85 M USD, representing a -26.25% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Zivo Bioscience since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Zivo Bioscience historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Zivo Bioscience

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Zivo Bioscience